Innoviva Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
INVA$19.00-0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
(a)
Index to Exhibits
| Incorporated by Reference | ||||
|---|---|---|---|---|
| ExhibitNumber | Description | Form | Exhibit | FilingDate/PeriodEnd Date |
| 3.1 | Amended and Restated Certificate of Incorporation | 8-K | 99.2 | 4/28/2016 |
| 3.2 | Amended and Restated Bylaws, amended and restated as of January 1, 2023 | 8-K | 3.1 | 1/4/2023 |
| 4.1 | Specimen certificate representing the common stock of the registrant | 10-K | 4.1 | 12/31/2006 |
| 4.2 | Indenture, dated as of January 4, 2013 by and between Theravance, Inc. and the Bank of New York Mellon Trust Company, N.A., as trustee | 8-K | 4.1 | 1/25/2013 |
| 4.3 | Form of 2.125% Convertible Subordinated Note Due 2023 (included in Exhibit 4.2) | 8-K | 4.2 | 1/25/2013 |
| 4.4 | Indenture (including form of Note) with respect to Innoviva’s 2.5% Convertible Senior Notes due 2025, dated as of August 7, 2017, between Innoviva and The Bank of New York Mellon Trust Company, N.A., as trustee | 8-K | 4.1 | 8/7/2017 |
| 4.5 | Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 | 10-K | 4.9 | 2/19/2020 |
| 4.6 | Indenture (including form of Note) with respect to Innoviva’s 2.125% Convertible Senior Notes due 2028, dated as of March 7, 2022, between Innoviva and The Bank of New York Mellon Trust Company, N.A., as trustee | 8-K | 4.1 | 3/8/2022 |
| 31.1 | Certification of Principal Executive Officer pursuant to Rules 13a‑14 pursuant to the Securities Exchange Act of 1934 | |||
| 31.2 | Certification of Chief Financial Officer pursuant to Rules 13a‑14 pursuant to the Securities Exchange Act of 1934 | |||
| 32* | Certifications Pursuant to 18 U.S.C. Section 1350 | |||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||
- Management contract or compensatory plan or arrangement.
- Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.